NEORx VERLUMA IMAGING AGENT FOR INITIAL STAGING OF SMALL CELL LUNG CANCER ACCURATE IN 82% OF PATIENTS; GAINS RECOMMENDATION FROM FDA COMMITTEE.
Executive Summary
NeoRx' monoclonal antibody imaging agent Verluma (technetium 99m nofetumomab merpentan) accurately staged 73 of 89 small cell lung cancer patients with a positive biopsy (82%) compared to 80 of 89 (90%) with the standard battery of tests, leading FDA's Oncologic Drugs Advisory Committee to recommend the diagnostic for approval for initial staging of SCLC in a 9-4 vote Dec. 14.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth